DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Bokf Na

Bokf Na reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 1.6% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 46,180 shares of the medical device company’s stock after selling 750 shares during the period. Bokf Na’s holdings in DexCom were worth $5,236,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of New Hampshire acquired a new stake in DexCom during the 1st quarter worth $1,508,000. Eagle Asset Management Inc. lifted its holdings in shares of DexCom by 21.5% in the 4th quarter. Eagle Asset Management Inc. now owns 1,756,216 shares of the medical device company’s stock valued at $217,929,000 after purchasing an additional 310,728 shares during the last quarter. Alberta Investment Management Corp boosted its position in shares of DexCom by 27.0% in the 4th quarter. Alberta Investment Management Corp now owns 323,335 shares of the medical device company’s stock valued at $40,123,000 after purchasing an additional 68,723 shares during the period. Artisan Partners Limited Partnership grew its stake in DexCom by 164.8% during the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after buying an additional 3,672,471 shares during the last quarter. Finally, Los Angeles Capital Management LLC grew its stake in DexCom by 62.5% during the 1st quarter. Los Angeles Capital Management LLC now owns 357,033 shares of the medical device company’s stock worth $49,520,000 after buying an additional 137,336 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DXCM. Redburn Atlantic started coverage on DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price objective for the company. UBS Group decreased their price target on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Wells Fargo & Company dropped their price objective on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research note on Friday, July 26th. Morgan Stanley decreased their target price on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research note on Friday, July 26th. Finally, Oppenheimer dropped their price target on DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $112.25.

DexCom Trading Up 0.5 %

Shares of DXCM stock opened at $68.82 on Friday. The stock has a market cap of $27.37 billion, a P/E ratio of 44.40, a P/E/G ratio of 2.12 and a beta of 1.18. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The business has a fifty day simple moving average of $83.24 and a 200-day simple moving average of $111.61.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.34 earnings per share. On average, analysts forecast that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other DexCom news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,483 shares of company stock valued at $201,708. 0.30% of the stock is owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.